Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT06104683
What this trial is testing

Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

Who this might be right for
Relapsing Multiple SclerosisMultiple Sclerosis
Loxo Oncology, Inc.
Not applicableStudy completedNCT06395909
What this trial is testing

Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Relapsing Multiple SclerosisClinically Isolated SyndromeRelapsing Remitting Multiple Sclerosis+1 more
Novartis 113
Testing effectiveness (Phase 2)Ended earlyNCT00484536
What this trial is testing

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Who this might be right for
Multiple Sclerosis
UCB Pharma 232
Post-approval studies (Phase 4)Study completedNCT03784898
What this trial is testing

Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

Who this might be right for
Multiple Sclerosis
Genzyme, a Sanofi Company 13
Post-approval studies (Phase 4)Study completedNCT03135249
What this trial is testing

Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis (MS)
University of Texas Southwestern Medical Center 9
Post-approval studies (Phase 4)Looking for participantsNCT07225361
What this trial is testing

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Who this might be right for
Multiple SclerosisMultiple Sclerosis (MS) - Relapsing-remitting
Northwestern University 40
Post-approval studies (Phase 4)Ended earlyNCT02241785
What this trial is testing

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies

Who this might be right for
Relapsing Multiple Sclerosis
Biogen 47
Testing effectiveness (Phase 2)Study completedNCT00109161
What this trial is testing

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
PDL BioPharma, Inc. 270
Not applicableStudy completedNCT01141751
What this trial is testing

An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany 334
Large-scale testing (Phase 3)Study completedNCT02201108
What this trial is testing

Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Genzyme, a Sanofi Company 166
Early research (Phase 1)Study completedNCT00813969
What this trial is testing

Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS

Who this might be right for
Relapsing-Remitting Multiple SclerosisSecondary Progressive Multiple SclerosisProgressive Relapsing Multiple Sclerosis
The Cleveland Clinic 24
Large-scale testing (Phase 3)Study completedNCT01199861
What this trial is testing

Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)

Who this might be right for
Relapsing Multiple Sclerosis
Novartis 138
Not applicableStudy completedNCT02519413
What this trial is testing

Tecfidera Lymphocyte Chart Review

Who this might be right for
Multiple Sclerosis
Biogen 483
Not applicableUnknownNCT01811290
What this trial is testing

A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Simnad, Virginia, M.D. 36
Testing effectiveness (Phase 2)Study completedNCT01639300
What this trial is testing

Safety Study of GNbAC1 in Multiple Sclerosis Patients

Who this might be right for
Multiple Sclerosis
GeNeuro Innovation SAS 10
Large-scale testing (Phase 3)Study completedNCT01127750
What this trial is testing

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

Who this might be right for
Relapsing Multiple Sclerosis
Novartis 2,417
Not applicableStudy completedNCT00464074
What this trial is testing

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue

Who this might be right for
Multiple Sclerosis
Biogen 89
Large-scale testing (Phase 3)Study completedNCT03623243
What this trial is testing

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

Who this might be right for
Multiple SclerosisRelapsing Multiple SclerosisAdvancing Multiple Sclerosis
Novartis Pharmaceuticals 185
Testing effectiveness (Phase 2)Study completedNCT00469378
What this trial is testing

Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
GlaxoSmithKline 46
Not applicableStudy completedNCT01080014
What this trial is testing

Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina

Who this might be right for
Multiple Sclerosis
Merck KGaA, Darmstadt, Germany 252
Next Page